News

Categories

March 5, 2025

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

February 25, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

February 18, 2025

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

February 13, 2025

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

January 30, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

January 8, 2025

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

December 12, 2024

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

November 21, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

November 21, 2024

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii), for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 7, 2024

Zymeworks Presents Preclinical Data on ZW171 at the Society for Immunotherapy of Cancer (SITC) Conference

November 5, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors